Form 8-K ReShape Lifesciences For: Jan 26
- Wall St ends higher as Yellen vows actions to safeguard deposits
- Wall Street digests Powell's comments on banks, rate cuts and inflation
- PacWest says it would not be 'prudent' to go ahead with capital raise; Analyst optimistic
- Block (SQ) shares plunge after Hindenburg claims it misleads investors with 'inflated metrics'
- Coinbase Wells Notice: Oppenheimer cuts; Mizuho says a third of revenue could be affected
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|(Address of principal executive offices)||(Zip Code)|
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|Item 8.01||Other Events.|
On January 26, 2023, ReShape Lifesciences Inc. (the “Company”) filed an Amendment No. 1 to its Registration Statement on Form S-1 (File No. 333-269207) (the “Registration Statement”) in connection with a proposed underwritten public offering of its securities. The preliminary prospectus that forms part of the Registration Statement includes certain updates to the description of the Company’s business and risk factors, which are attached hereto as Exhibit 99.1 and 99.2, respectively, and are incorporated herein by reference. The information in this Item 8.01 (including Exhibits 99.1 and 99.2) should be read in conjunction with the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
This Current Report on Form 8-K, including the exhibits hereto, shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, which will be made only by means of a written prospectus meeting the requirements of Section 10 of the Securities Act, nor shall there be any sale of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
|Item 9.01||Financial Statements and Exhibits.|
|99.1||Updated Business Summary|
|99.2||Updated Risk Factors|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|RESHAPE LIFESCIENCES INC.|
|By:||/s/ Paul F. Hickey|
|Paul F. Hickey|
|President and Chief Executive Officer|
Date: January 27, 2023
ATTACHMENTS / EXHIBITS
XBRL TAXONOMY EXTENSION SCHEMA
XBRL TAXONOMY EXTENSION LABEL LINKBASE
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ReShape Lifesciences Announces Formation of International Scientific Advisory Board
- Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary
- CarMax Announces Fourth Quarter Conference Call
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!